Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Phase 1/2 trial of vorinostat in patients with sickle cell disease who have not benefitted from hydroxyurea.

Literature DB >> 26045597

Phase 1/2 trial of vorinostat in patients with sickle cell disease who have not benefitted from hydroxyurea.

Maureen M Okam¹, Erica B Esrick², Elyse Mandell³, Federico Campigotto⁴, Donna S Neuberg⁵, Benjamin L Ebert¹.

Abstract

Entities: Chemical Species

Mesh：

Substances：

Year: 2015 PMID： 26045597 PMCID： PMC4458806 DOI： 10.1182/blood-2015-03-635391

Source DB: PubMed Journal: Blood ISSN： 0006-4971 Impact factor: 22.113

× No keyword cloud information.

10 in total

1. Induction of human gamma globin gene expression by histone deacetylase inhibitors.

Authors: Hua Cao; George Stamatoyannopoulos; Manfred Jung
Journal: Blood Date: 2003-08-14 Impact factor: 22.113

Review 2. Fetal hemoglobin in sickle cell anemia.

Authors: Idowu Akinsheye; Abdulrahman Alsultan; Nadia Solovieff; Duyen Ngo; Clinton T Baldwin; Paola Sebastiani; David H K Chui; Martin H Steinberg
Journal: Blood Date: 2011-04-13 Impact factor: 22.113

3. The number of people with sickle-cell disease in the United States: national and state estimates.

Authors: David C Brousseau; Julie A Panepinto; Mark Nimmer; Raymond G Hoffmann
Journal: Am J Hematol Date: 2010-01 Impact factor: 10.047

4. Valproic acid and augmentation of fetal hemoglobin in individuals with and without sickle cell disease.

Authors: R Selby; E Nisbet-Brown; R K Basran; L Chang; N F Olivieri
Journal: Blood Date: 1997-07-15 Impact factor: 22.113

5. Hydroxycarbamide in very young children with sickle-cell anaemia: a multicentre, randomised, controlled trial (BABY HUG).

Authors: Winfred C Wang; Russell E Ware; Scott T Miller; Rathi V Iyer; James F Casella; Caterina P Minniti; Sohail Rana; Courtney D Thornburg; Zora R Rogers; Ram V Kalpatthi; Julio C Barredo; R Clark Brown; Sharada A Sarnaik; Thomas H Howard; Lynn W Wynn; Abdullah Kutlar; F Daniel Armstrong; Beatrice A Files; Jonathan C Goldsmith; Myron A Waclawiw; Xiangke Huang; Bruce W Thompson
Journal: Lancet Date: 2011-05-14 Impact factor: 79.321

6. Chemical genetic strategy identifies histone deacetylase 1 (HDAC1) and HDAC2 as therapeutic targets in sickle cell disease.

Authors: James E Bradner; Raymond Mak; Shyam K Tanguturi; Ralph Mazitschek; Stephen J Haggarty; Kenneth Ross; Cindy Y Chang; Jocelyn Bosco; Nathan West; Elizabeth Morse; Katherine Lin; John Paul Shen; Nicholas P Kwiatkowski; Nele Gheldof; Job Dekker; Daniel J DeAngelo; Steven A Carr; Stuart L Schreiber; Todd R Golub; Benjamin L Ebert
Journal: Proc Natl Acad Sci U S A Date: 2010-06-28 Impact factor: 11.205

7. Sustained induction of fetal hemoglobin by pulse butyrate therapy in sickle cell disease.

Authors: G F Atweh; M Sutton; I Nassif; V Boosalis; G J Dover; S Wallenstein; E Wright; L McMahon; G Stamatoyannopoulos; D V Faller; S P Perrine
Journal: Blood Date: 1999-03-15 Impact factor: 22.113

8. Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia.

Authors: S Charache; M L Terrin; R D Moore; G J Dover; F B Barton; S V Eckert; R P McMahon; D R Bonds
Journal: N Engl J Med Date: 1995-05-18 Impact factor: 91.245

9. Induction of fetal hemoglobin production in subjects with sickle cell anemia by oral sodium phenylbutyrate.

Authors: G J Dover; S Brusilow; S Charache
Journal: Blood Date: 1994-07-01 Impact factor: 22.113

10. A short-term trial of butyrate to stimulate fetal-globin-gene expression in the beta-globin disorders.

Authors: S P Perrine; G D Ginder; D V Faller; G H Dover; T Ikuta; H E Witkowska; S P Cai; E P Vichinsky; N F Olivieri
Journal: N Engl J Med Date: 1993-01-14 Impact factor: 91.245

10 in total

5 in total

Phase 1/2 trial of vorinostat in patients with sickle cell disease who have not benefitted from hydroxyurea.

1. Induction of human gamma globin gene expression by histone deacetylase inhibitors.

Review 2. Fetal hemoglobin in sickle cell anemia.

3. The number of people with sickle-cell disease in the United States: national and state estimates.

4. Valproic acid and augmentation of fetal hemoglobin in individuals with and without sickle cell disease.

5. Hydroxycarbamide in very young children with sickle-cell anaemia: a multicentre, randomised, controlled trial (BABY HUG).

6. Chemical genetic strategy identifies histone deacetylase 1 (HDAC1) and HDAC2 as therapeutic targets in sickle cell disease.

7. Sustained induction of fetal hemoglobin by pulse butyrate therapy in sickle cell disease.

8. Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia.

9. Induction of fetal hemoglobin production in subjects with sickle cell anemia by oral sodium phenylbutyrate.

10. A short-term trial of butyrate to stimulate fetal-globin-gene expression in the beta-globin disorders.

Review 1. Beyond hydroxyurea: new and old drugs in the pipeline for sickle cell disease.

2. Advances in new drug therapies for the management of sickle cell disease.

Review 3. Erythropoiesis: insights into pathophysiology and treatments in 2017.

Review 4. HDAC inhibitors as antifibrotic drugs in cardiac and pulmonary fibrosis.

Review 5. Histone Deacetylases (HDACs) and Atherosclerosis: A Mechanistic and Pharmacological Review.